Captopril suppression test
Captopril Suppression Test
The Captopril Suppression Test is a diagnostic procedure used primarily to evaluate and diagnose conditions related to abnormal renin activity, particularly primary aldosteronism and renovascular hypertension. This test involves the administration of captopril, an angiotensin-converting enzyme inhibitor, and subsequent measurement of aldosterone and renin levels to assess their response to the drug. The captopril suppression test is a critical tool in the differential diagnosis of hypertension and helps in identifying the underlying cause, which is essential for determining the most appropriate treatment plan.
Procedure[edit | edit source]
The captopril suppression test is conducted in a controlled clinical setting. The procedure involves several steps:
- Baseline blood samples are collected to measure initial levels of plasma aldosterone concentration (PAC) and plasma renin activity (PRA).
- The patient is then administered an oral dose of captopril, typically 25 to 50 mg.
- After a waiting period, usually 60 minutes, blood samples are again collected to measure the post-captopril levels of PAC and PRA.
- The results are analyzed by comparing the baseline and post-captopril measurements. A decrease in aldosterone levels in response to captopril indicates normal renin and aldosterone activity. Conversely, little to no change in aldosterone levels suggests the presence of conditions like primary aldosteronism.
Indications[edit | edit source]
The captopril suppression test is indicated for patients with:
- Hypertension, especially those with difficult-to-control blood pressure
- Hypokalemia (low potassium levels)
- Suspected primary aldosteronism
- Suspected renovascular hypertension
Interpretation of Results[edit | edit source]
- Normal Response: A significant decrease in aldosterone levels after captopril administration, indicating normal renin and aldosterone activity.
- Abnormal Response: Minimal or no decrease in aldosterone levels, suggesting the presence of conditions such as primary aldosteronism or renin-independent aldosteronism.
Risks and Considerations[edit | edit source]
While the captopril suppression test is generally safe, it may cause adverse reactions in some patients, including:
- Hypotension (low blood pressure)
- Acute renal failure, particularly in patients with bilateral renal artery stenosis
- Allergic reactions to captopril
Patients should be closely monitored throughout the test for any adverse effects. It is also important to consider patient history and concurrent medications that may affect the test's accuracy.
Conclusion[edit | edit source]
The captopril suppression test is a valuable diagnostic tool in the evaluation of hypertension and its underlying causes. By assessing the response of aldosterone and renin levels to captopril, healthcare providers can better understand the etiology of a patient's hypertension and tailor treatment accordingly. However, the test must be conducted with caution, considering potential risks and individual patient factors.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD